Novartis Cosentyx gets FDA OK for new spondyloarthritis indication

• FDA approval for Cosentyx is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis (axSpA) disease spectrum
• There are an estimated 2.7M people living with axial spondyloarthritis (axSpA) in the US; however, it remains significantly underdiagnosed(1,2)
• nr-axSpA approval is the fourth indication for Cosentyx, which is backed by five years of clinical data supporting long-term safety and efficacy across moderate to severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)(3-8)

https://www.biospace.com/article/releases/novartis-cosentyx-receives-fda-approval-for-new-indication-to-treat-active-non-radiographic-axial-spondyloarthritis/